Effect of COVID-19 Pandemic on Behavioral and Pharmacological Treatment Outcomes in ADHD Childre
- Conditions
- ADHD childrenCOVID-19 Pandemic, Behavioral and Pharmacological Treatment Outcomes , Attention Deficit Hyperactivity Disorder (ADHD) Children
- Registration Number
- TCTR20220714003
- Lead Sponsor
- Faculty of Pharmaceutical Sciences, Burapha University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 80
1) was Thai people with 13-digit identification.
2) aged 14 years or younger during COVID-19 outbreak (after 3 April 2020).
3) were diagnosed Attention Deficit Hyperactivity Disorder (ADHD): ICD-10-TM codes F90 before and during COVID-19 outbreak.
4) had at least one patient data recorded or medical record before and during COVID-19 outbreak.
5) had records of pharmacological outcome or behavioral outcome.
6) had records of demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.
1)denied to participate in this project.
2)were diagnosed Autistic traits who would be represented the unobvious differentiation of pharmacological outcome and behavioral outcome.
3) loss of follow up or loss of contact information.
4) were study subjects with missing data on pharmacological outcome, behavioral outcome, demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method behavioral outcomes survey date parents SNAP IV rating scale or health care provider assessment
- Secondary Outcome Measures
Name Time Method Pharmacological outcomes survey date medication possession ratio (MPR) or medication adherence assessment by physician or medication withdraw period more than 6 months in the comparison of before and after COVID-19 pandemic